Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































Medicaid Alternative Payment Models for Prescription Drugs: Do They Add Value for States?
/in Policy Oklahoma Webinars Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Prescription Drug Pricing, Quality and Measurement, Value-Based Purchasing /by NASHP WritersWednesday, Dec. 12, 2018 2-3 pm (EST) Listen to the Webinar. Download the Slides. As states struggle with the increasing cost of prescription drugs, they are testing various alternative payment models (APMs). The Oklahoma Health Care Authority is a national leader with four alternative payment models in the form of direct contracts with pharmaceutical manufacturers. […]
NASHP Partners with Mathematica to Strengthen State Rx Transparency Laws
/in Policy Blogs Prescription Drug Pricing /by NASHP WritersThe National Academy for State Health Policy (NASHP) is partnering with Mathematica Policy Research to help states increase transparency and accountability to address rising prescription drug prices. This state-directed partnership will support the alignment of data collection and enable cross-state analyses. Currently, California, Oregon, Nevada, Connecticut, and Vermont require manufacturers to report on price increases […]
2018 Elections and State Health Policy: Expect More Innovation
/in Policy Blogs Behavioral/Mental Health and SUD, Chronic and Complex Populations, Chronic Disease Prevention and Management, Cost, Payment, and Delivery Reform, Health Coverage and Access, Health IT/Data, Health System Costs, Healthy Child Development, Maternal, Child, and Adolescent Health, Medicaid Expansion, Physical and Behavioral Health Integration, Population Health, Prescription Drug Pricing, Social Determinants of Health, State Insurance Marketplaces, State Rx Legislative Action, Workforce Capacity /by Anita Cardwell and Sarah LanfordSignificant state health policy changes are on the horizon as a result of Tuesday’s elections, which ushered in new governors and political changes in state legislatures across the country. Seven governorships (IL, ME, MI, NV, NM, KS, and WI) will switch parties and be steered by Democrats who all campaigned on health policy proposals. The […]
States Take Administrative Actions to Curb Medicaid Drug Costs
/in Policy Ohio, Vermont, West Virginia Blogs Administrative Actions, Cost, Payment, and Delivery Reform, Health Coverage and Access, Medicaid Managed Care, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer ReckDuring the 2018 legislative session, 28 states passed 45 laws to curb the rising cost of prescription drugs. In addition to legislative solutions, states are taking administrative action to better manage state spending on Medicaid pharmacy benefits. Ohio, West Virginia, and Vermont offer examples of states taking innovative administrative approaches to rein in drug costs. […]
A Snapshot of the Key Health Policy Issues at Play in 2018 Governors’ Races
/in Policy Blogs Administrative Actions, Behavioral/Mental Health and SUD, Chronic and Complex Populations, Chronic Disease Prevention and Management, Cost, Payment, and Delivery Reform, Health Coverage and Access, Health Equity, Health System Costs, Integrated Care for Children, Integrated for Pregnant/Parenting Women, Maternal Health and Mortality, Maternal, Child, and Adolescent Health, Medicaid Expansion, Population Health, Prescription Drug Pricing, Safety Net Providers and Rural Health, Social Determinants of Health, State Insurance Marketplaces, State Rx Legislative Action, Workforce Capacity /by Anita CardwellWith elections just three weeks away, governors’ races in 36 states – with 17 open seats – are down to the wire and important health policy issues, such as Medicaid expansion, stabilizing insurance markets, public options, and prescription drug price controls, are at play in most of them. The National Academy for State Health Policy […]
Comparison of State Pharmacy Benefit Managers Laws
/in Policy Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffOklahoma Signs the Nation’s First State Medicaid Value-Based Contracts for Rx Drugs
/in Policy Oklahoma Blogs Administrative Actions, Chronic Disease Prevention and Management, Cost, Payment, and Delivery Reform, Health System Costs, Population Health, Prescription Drug Pricing, State Rx Legislative Action, Value-Based Purchasing /by Jennifer ReckOn the heels of Oklahoma’s first-in-the-nation, value-based purchasing deal to improve adherence to an antipsychotic drug, the state’s Medicaid agency just signed its second value-based contract for a prescription drug used to treat serious bacterial skin infections. While several private insurers have initiated value-based contracting, which links payments to a drug’s effectiveness and outcome, Oklahoma […]
NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database
/in Policy California, Connecticut, Nevada, Oregon, Vermont Administrative Actions, Legal Resources, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer ReckNASHP’s Center for State Rx Drug Pricing seeks a partner to provide technical and strategic expertise to help a workgroup of state officials from California, Nevada, Oregon, Connecticut, and Vermont implement their drug cost transparency laws and help Maine and New Hampshire develop transparency programs as mandated by recent legislation. This work will help all […]
As States Take the Lead to Address Drug Costs, Federal Action Follows
/in Policy Blogs Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP Staff*Update: On Oct. 10, 2018, President Trump signed two bills designed to increase prescription drug price transparency by prohibiting gag clauses, which prevent pharmacists from disclosing lower-cost drug options to consumers. One bill prohibits gag clauses under Medicare Part D starting in 2020 and the other affects private insurance markets and goes into effect immediately. […]
New NASHP Model Legislation Helps States Bring Transparency to Pharmacy Benefit Managers
/in Policy Blogs Administrative Actions, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Jane HorvathThe National Academy for State Health Policy (NASHP) has released model legislation to help states shed light on the opaque business practices of pharmacy benefit managers (PBMs). States can use the model bill to require the licensing of PBMs, ban gag clauses that prevent pharmacists from sharing lower-price drug options with consumers, and require more […]